#AANAM – COVID-19 Often Leads to Flares in MS Patients, Survey Finds multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Ublituximab, an investigational therapy for relapsing forms of multiple sclerosis (MS), significantly outperformed Aubagio (teriflunomide) at reducing patients’ annualized relapse rates and lowering the number of brain lesions over nearly two years, according to data from the ULTIMATE clinical trials.
“The results of the ULTIMATE I and II studies show that not only did ublituximab effectively reduce relapses in patients with RMS, but had a profound effect on suppressing inflammatory activity,” Steinman, the global study chair for the two trials, said in a press release.
#AANAM – Disease Severity, Job Loss High in Black RRMS Patients in US multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Kesimpta (ofatumumab) may now be prescribed through the National Health Service (NHS) of England and Wales as an at-home, self-administered treatment for people with relapsing-remitting multiple sclerosis (RRMS) who are either having relapses or have other evidence of MS activity.
A poster presentation at the AAN meeting, based on Phase 3 data in newly diagnosed patients, also showed it effective at preventing disability progression in the absence of a relapse in this group.
The National Institute for Health Care and Excellence (NICE) made the recommendation to include Kesimpta in the NHS, allowing RRMS patients to access it at low and fixed prices, following Kesimpta’s recent approval in the U.K. for relapsing forms of multiple sclerosis (MS).
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the proteins neurofilament light chain, known as NfL, and glial fibrillary acidic protein, or GFAP, are associated with an increased risk of worsening disability, new research shows.
Measuring levels of certain proteins in the blood can provide important information about a person’s health. NfL is released into the blood when neurons or nerve cells are damaged or destroyed. As such, levels of NfL in the blood are indicative of injury in the nervous system. GFAP, meanwhile, is associated with the activity of star-shaped neural support cells called astrocytes, and also is a marker of nervous system injury.